Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 11:41 AM ET

Biotechnology

Company Overview of Adamas Pharmaceuticals, Inc.

Company Overview

Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate ADS-5102, which completed the Phase II/III clinical trial for the treatment of Parkinson's disease, known as levodopa induced dyskinesia. Its product portfolio also includes memantine-based therapeutics, which include Namenda XR, a treatment of moderate to severe dementia associated with Alzheimer's disease; and Namzaric, a once-daily fixed-dose combination of Namenda XR, which is being co-developed with Forest Laboratories, Inc. The company was f...

1900 Powell Street

Suite 750

Emeryville, CA 94608

United States

Founded in 2000

46 Employees

Phone:

510-450-3500

Fax:

510-428-0519

Key Executives for Adamas Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 51
Total Annual Compensation: $748.8K
Chief Operating Officer
Age: 49
Total Annual Compensation: $436.1K
Senior Vice President of Product Development
Age: 62
Total Annual Compensation: $503.0K
Compensation as of Fiscal Year 2014.

Adamas Pharmaceuticals, Inc. Key Developments

Adamas Pharmaceuticals, Inc. Announces Additional Findings from Phase 2/3 Study Evaluating ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia

Adamas Pharmaceuticals, Inc. announced additional findings from its Phase 2/3 study (EASED) evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a movement disorder associated with the treatment of Parkinson's disease. Patient diary data were analyzed to characterize the time course of troublesome LID and other Parkinson's disease states during waking hours, synchronized to the patients' wake-up times as well as to elucidate the impact of treatment with ADS-5102. These data showed that troublesome LID was reported throughout the day. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. In contrast, placebo-treated patients reported little change in their dyskinesia. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. ON time is the period when the effects of levodopa provide relief from symptoms of Parkinson's disease. In this post hoc analysis, to better understand motor complications experienced throughout waking hours, a data set was assembled synchronized according to each patient's wake-up time. This analysis included data from patient diaries (n= 62) at baseline and after eight weeks of treatment with either ADS-5102 (n=42, all doses) or placebo (n=20). This analysis revealed that prior to treatment (baseline), study participants experienced, over the course of the day, a complex and dynamic pattern of Parkinson's disease states, including ON time with and without troublesome LID and OFF time. After eight weeks of placebo treatment, there was little change in this pattern. In contrast, the majority of ADS-5102-treated individuals were able to maintain ON time without troublesome LID throughout the waking day, for at least 14 hours after waking up. ADS-5102 was generally well tolerated and reported adverse event terms were consistent with Parkinson's disease and the known amantadine safety profile.

Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients with Walking Impairment

Adamas Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical trial with ADS-5102 (amantadine HCl) in individuals with multiple sclerosis (MS) who have walking impairment. The company to initiate this Phase 2 trial in MS patients with walking impairment to further its understanding of the safety and tolerability of ADS-5102 and to obtain data to guide its development efforts. As its Phase 3 trials of ADS-5102 in levodopa-induced dyskinesia continue to move forward, the company is identifying additional indications that will allow to leverage its wholly-owned, extended-release formulation of amantadine and bring new treatment options to individuals in need. This Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled, two arm, parallel group study of ADS-5102 in 60 individuals with MS who have walking impairment. All participants will be on a stable regimen of MS medications for at least 30 days prior to screening and will continue the same dose and regimen for the duration of their study participation. The primary study objective is to evaluate the safety and tolerability of ADS-5102 dosed at 340 mg once daily at bedtime in an MS population. Efficacy measurements will include assessments of walking and fatigue. The treatment duration will be four weeks with top-line results anticipated in 2016.

Adamas Pharmaceuticals Seeks Acquisitions

Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) is looking for acquisition opportunities. Adamas Pharmaceuticals has filed a shelf registration in the amount of $150 million and except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the shares of our common stock offered by us hereunder, if any, for working capital, capital expenditures and other general corporate purposes, which may include costs of funding future acquisitions or for any other purpose we describe in the applicable prospectus supplement

Similar Private Companies By Industry

Company Name Region
Abide Therapeutics, Inc. United States
Pyramid Biological Corporation United States
Cortexyme, Inc. United States
Therapeutic Peptides, Inc. United States
Jade Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Adamas Pharmaceuticals, Inc., please visit www.adamaspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.